Summary. The Sca-1 surface glycoprotein is used routinely as a marker for haematopoietic stem cell enrichment. Two allelic genes, Ly-6A and Ly-6E, encode this marker and appear to be differentially regulated in haematopoietic cells and haematopoietic stem cells. The Sca-1 protein has been shown to be expressed at a greater frequency in these cells from Ly-6A strains of mice. To study the speci®c expression pattern and haematopoietic regulation of the Ly-6A gene, we constructed a 14 kb cassette from a genomic Ly-6A fragment, inserted a lacZ reporter gene and created transgenic mice. We found that the Ly-6A lacZ transgene was expressed in the haematopoietic tissues and predominantly in the T-lymphoid lineage. Some expression was also found in the B-lymphoid and myeloid lineages. We demonstrated functional haematopoietic stem cell enrichment by sorting for b-galactosidase-expressing cells from the bone marrow. In addition, we found an interesting embryonic expression pattern in the AGM region, the site of the ®rst haematopoietic stem cell generation. Surprisingly, when compared with data from Ly-6E lacZ transgenic mice, our results suggest that the Ly-6A cassette does not improve lacZ marker gene expression in haematopoietic cells.
Enrichment and characterization of the stem cells at the foundation of the haematopoietic hierarchy has relied on the Sca-1 phosphatidylinositol-linked cell surface glycoprotein marker . Through¯uorescence-activated cell sorting using a monoclonal antibody speci®c for Sca-1, haematopoietic stem cells (HSC) can be enriched approximately 100-fold from adult bone marrow and, together with antibodies speci®c for other cell surface markers (i.e. Thy-1 lo , c-kit or depletion for cells with mature lineage markers), a greater than 1000-fold enrichment can be obtained Okada et al, 1992) .
The Sca-1 protein is encoded by the strain-speci®c allelic genes, Ly-6E and Ly-6A (van de Rijn et al, 1989; Khan et al, 1990; Stanford et al, 1992; Sinclair & Dzierzak, 1993) , which are members of the multigenic Ly-6 family (LeClair et al, 1986; Kamiura et al, 1992) . The family consists of at least 18 highly homologous cross-hybridizing genes with diverse and overlapping patterns of expression (Kimura et al, 1984) . Owing to the homologies of the Ly-6 family of genes and proteins, and the suspected overlapping roles in cell adhesion played by members of this family, functional studies have been dif®cult (Bamezai & Rock, 1995; Stanford et al, 1997) . Sca-1 protein expression is complex within Ly-6A and Ly-6E strains of mice (Kimura et al, 1984; van de Rijn et al, 1989; Spangrude & Brooks, 1993) . The Ly-6A and Ly-6E genes differ only by three nucleotides in the coding sequence, resulting in two amino acid changes (LeClair et al, 1986; Reiser et al, 1988) . Both gene products express the Sca-1 epitope recognized by the antibody E13± 161±7 (LeClair et al, 1986; Rock et al, 1986; Palfree et al, 1987; Reiser et al, 1988) . Both genes are interferon inducible, but the Ly-6A allele appears to be more widely and highly expressed (Kimura et al, 1984; Rock et al, 1986; Spangrude & Brooks, 1993) . Strains of mice with the Ly-6A gene express Sca-1 on 10± 20% of adult thymocytes and 50±70% of peripheral T lymphocytes, while strains with the Ly-6E gene express Sca-1 on 5±10% of adult thymocytes and 10±15% of peripheral T lymphocytes. Similarly, Ly-6A strains of mice express Sca-1 on virtually all (99%) marrow repopulating cells, while Ly-6E strains express Sca-1 on only 25% of these cells (Spangrude & Brooks, 1993) . Nonetheless, Sca-1 remains an important marker of HSCs and its gene regulatory elements are of current research interest to direct expression to HSCs for potential therapeutic applications.
Previously, the Ly-6E transcriptional elements have been examined. Upstream cis-acting elements involved in regulating in vitro expression of Ly-6E have been identi®ed (Khan et al, 1990 (Khan et al, , 1993 and sequence comparisons suggest that similar 5¢ control elements are present in the Ly-6A promoter (McGrew & Rock, 1991) . DNaseI hypersensitive site (HSS) mapping of both the Ly-6E and Ly-6A alleles show almost identical patterns (Sinclair & Dzierzak, 1993) . Deletion studies using the Ly-6E and Ly-6A genes reveal that the region containing the two most distal 3¢ HSS are responsible for high level, c interferon-induced expression in vitro (Sinclair et al, 1996; Ma et al, 2001) . Furthermore, this 3¢ region is necessary in the context of a 14 kb Ly-6E expression cassette for high-level tissuespeci®c expression of a lacZ marker gene in transgenic mice (Miles et al, 1997) . However, in such transgenic mice, it was found that some but not all HSCs can be sorted based on lacZ expression, suggesting that the Ly-6E expression cassette is not optimal for HSC expression in vivo. As subtle differences exist in HSS between the Ly-6E and Ly-6A alleles (Sinclair et al, 1996) and the Ly-6A gene product has been shown to be expressed in 100% of marrow repopulating cells, it was therefore of great interest to examine the Ly-6A sequences as a source for HSC-speci®c regulatory elements.
Thus, we cloned a lacZ reporter gene into a 14 kb Ly-6A gene cassette and generated transgenic mice. Here we present data from studies examining the differences in expression patterns and levels of Ly-6A lacZ transgene expression with that from a previously described Ly-6E lacZ transgene. In general, we found that the Ly-6A lacZ transgene is predominantly expressed in the cells of the T-lymphoid lineage. Moreover, we have shown that the Ly-6A lacZ transgene facilitates a > 100-fold enrichment of bone marrow HSCs. Surprisingly, while the Ly-6A lacZ transgene expression pattern in embryos was slightly more widespread than that of the Ly-6E lacZ transgene, the expected allele-speci®c differences in haematopoietic cell expression were not observed.
MATERIALS AND METHODS
Constructs and transgenic mice. The 14 kb Ly-6A cassette (Ly-6A14) was constructed as described previously (Ma et al, 2001) . The lacZ gene in p610ZA (gift of D. Meijer) was modi®ed, converting a 3¢ Sma1 site to a Nar1 site using oligonucleotide adaptors. The 3á6 kb lacZ Nar1 fragment was cloned into Ly-6A14 to generate pLAZ.
Fertilized (C57BL/10´CBA)F1 oocytes were microinjected with a 17á6-kb Not1 fragment containing the Ly-6A lacZ gene from pLAZ ( Fig 1A) . This fragment was gel puri®ed for removal of all vector sequences. Positive founder animals were bred with (C57BL/10´CBA)F1 mice and lines were maintained as heterozygotes. The C57BL/10 strain contains an endogenous Ly-6A allele and the CBA strain contains an endogenous Ly-6E allele. (C57BL/10´CBA)F1 mice co-dominantly express both alleles. Southern blot analysis of tail DNA was used to identify founder transgenic mice.
DNA and RNA analysis. Genomic DNA (5±10 lg) for Southern blot analysis (Miles et al, 1997) was digested using BamH1 and electrophoresed through 1% agarose/ Tris, acetate, EDTA gels prior to transfer to Hybond-N membranes. Transgene copy number controls were generated by addition of appropriate amounts of pLAZ to nontransgenic genomic DNA. Filters were probed with lacZ and Thy-1 gene fragments. Normalization for DNA content of each lane was performed after phosphorimage analysis of Thy-1 signal. Copy number was determined subsequently by comparing the lacZ signal obtained from the transgenic mice with that of the plasmid controls on the linear portion of the standard curve. Hybridization with the Thy1 probe (DNA normalization control) and lacZ probe (transgene) was performed and the signal detected by phosphorimaging was compared with plasmid copy controls for the determination of transgene copy number (indicated below each lane) in AZ1 and AZ2 transgenic lines. (C) Northern blot of total RNA from tissues of Ly-6A lacZ transgenic lines. Hybridization was performed with a lacZ probe for transgene expression and Ly-6A/ E-speci®c probe for endogenous gene expression. Tissues of a BL1b and a non-transgenic control are also shown. K kidney, L lymph node, T thymus, S spleen, B bone marrow.
Total cellular RNA for Northern blot analysis was prepared using the lithium chloride/urea method and 5±15 lg was fractionated on 1% agarose/formaldehyde gels (Fraser et al, 1990) prior to transfer to Hybond-N membranes. Filters were probed with lacZ and Ly-6E cDNA fragments.
Probes used for hybidization to Southern or Northern ®lters were labelled using the random oligonucleotide priming procedure incorporating [ 32 P]-ATP. The fragments used were as follows: 1á1 kb BamH1±EcoRV lacZ containing fragment from p610ZA; 1á2 kb Xba1±Nru1 Thy-1 gene fragment from pD7 (Spanopoulou et al, 1988) ; 761 bp EcoR1 Ly-6E cDNA fragment from pLy6á1±2R (LeClair et al, 1986) . After hybridization, ®lters were washed to a stringency of 0á2´saline sodium citrate (SSC)/0á1% sodium dodecyl sulphate (SDS) and exposed to a phosphorimager screen for quanti®cation using IMAGEQUANT software.
Genomic DNA (200 ng) from the peripheral blood of transplant recipients was analysed using polymerase chain reaction (PCR) with oligonucleotide primers for myogeninspeci®c sequences: (myo1) 5¢-TTACGTCCATCGTGGACA-GC-3¢ and (myo2) 5¢-TGGGCTGGGTGTTAGTCTTA-3¢; and for lacZ-speci®c sequences: (lacZ1) 5¢-GCGACTTCCAGTTCA-ACATC-3¢ and (lacZ2) 5¢-GATGAGTTTGGACAAACCAC-3¢.
DNA was subjected to an initial 5 min denaturation at 94°C followed by 30 cycles of denaturation (5 s at 94°C), annealing (30 s at 60°C), elongation (30 s at 72°C). Serial dilutions of blood DNA from a transgenic animal were used as a control to evaluate the levels of donor cell reconstitution in transplanted mice.
b-galactosidase and antibody staining. For analysis of b-galactosidase expression in transgenic bone marrow, thymus, spleen and lymph node, 10 6 cells were suspended in 100 ll of prewarmed phosphate-buffered saline (PBS) with 5% fetal calf serum (FCS) prior to loading with 100 ll of 2 mmol/l uorescein di-(b-D-galactopyranoside) (FDG) in H 2 O. Cells were incubated at 37°C for 60 s. The uptake was stopped by the addition of 2 ml of ice-cold PBS with 5% FCS and the reaction was allowed to proceed for 1±3 h on ice in the dark. Propidium iodide (PI, 1 lg/ml) or 7-amino-actinomycin D (7AAD, 2á5 lg/ml; Pharmingen, Alphen a/d Rijn, The Netherlands) was used to exclude dead cells. A FACSCAN and FACSVANTAGE SE (Becton-Dickinson, Alphen a/d Rijn, The Netherlands) were used for analysis and sorting. Sca-1, CD4, CD8, B220 and Mac-1 antibodies were direct phycoerythrin (PE) conjugates (Pharmingen). Brie¯y, after 1±2 h of FDG staining, 10 6 cells were stained with antibody, incubated on ice for 30 min and washed three times in cold PBS with 5% FCS.
Whole embryos were isolated into ice-cold PBS, ®xed in 1 ml of X-gal ®x (1% formaldehyde, 0á2% gluteraldehyde) at 4°C for 1 h and stained overnight at room temperature in 1 mg/ml X-gal (Sigma, Zwijndrecht, The Netherlands). After staining, embryos were dehydrated through increasing concentrations of ethanol in ice-cold PBS and mounted in paraf®n wax. Sections (6±10 lm) were cut onto APES (3-aminopropyltriethoxysilane, Sigma, Zwijndrecht, The Netherlands)-coated microscope slides and dried overnight at room temperature. Slides were dewaxed in Histoclear and rehydrated through decreasing concentrations of ethanol before standard counterstaining with haematoxylin-eosin and mounting.
Bone marrow transplantation. Donor transgenic bone marrow cells for transplantations were FDG, Sca-1 and Hoechst 33258 stained ex vivo in PBS with 5% FCS. FACSsorted cells were counted, diluted and suspended in a ®nal volume of 500 ll of PBS for intravenous injection into the tail vein of male (C57BL/10´CBA)F1 mice. On the day of transfer, the recipients were exposed to a split dose (3 h interval) of 900 rad irradiation from a 137 Cs source. Adult (C57BL/10´CBA)F1 spleen cells ( 2´10 5 ) were co-injected with the donor cells to promote short-term survival. All recipients were housed in ®lter-top isolators and received 1á6 g/l neomycin in drinking water for at least 1 month. Peripheral blood was taken at 1 and 4 months post transplantation for analysis.
RESULTS
The Ly-6A lacZ transgene is expressed in adult mice The Ly-6A gene was previously cloned and analysed for in vitro expression in haematopoietic cells. A genomic expression cassette containing a distal 3¢ fragment with strong DNaseI hypersensitive sites (Sinclair & Dzierzak, 1993 ) was found to yield high level, c interferon-induced expression (Ma et al, 2001) . To determine if this cassette could be used to express exogenous genes in haematopoietic stem cells in vivo, we inserted a lacZ marker gene into an engineered Cla1 site in the ®rst untranslated exon of the Ly-6A gene (Fig 1A; Ma et al, 2001 ). Two transgenic mouse lines were produced with the Ly-6A lacZ construct: AZ1 and AZ2. Southern blotting of DNA from these established mouse lines was compared with DNA from a previously generated Ly-6E lacZ transgenic line (BL1b) which, in the homozygous state, contains eight copies of this allelic transgene. Figure 1B shows that AZ1 contains eight copies and AZ2 contains > 20 copies of the Ly-6A lacZ transgene in the hemizygous state. Northern blot analysis was performed on RNA derived from various haematopoietic and nonhaematopoietic tissues of these transgenic lines (Fig 1C) . High level Ly-6A lacZ transgene expression was found in the kidney of both the AZ1 and AZ2 transgenic lines and was similar to that observed in the BL1b transgenic line. Other tissues, such as the bone marrow, spleen and thymus, show little or undetectable expression. No expression was found in a non-transgenic littermate control. In general, the tissuespeci®c expression pattern followed closely the transcription of the endogenous Ly-6A/E gene. Interestingly, the higher copy AZ2 line showed equivalent levels of expression to the AZ1 and BL1b lines using this analysis. Thus, the speci®c expression pattern of the Ly-6A lacZ transgene was similar in both AZ1 and AZ2 adult tissues and was consistent with the general pattern in several lines of Ly-6E lacZ transgenic mice (Miles et al, 1997) including BL1b.
Ly-6A lacZ transgene is expressed in haematopoietic cells
Although Northern blot analysis showed little expression in haematopoietic tissues, a more sensitive method, FDG-FACS, was performed on cells from thymus, spleen, lymph node and bone marrow of transgenic mice to detect b-galactosidase expression. To determine if allelic-speci®c differences in transgene expression could be observed, the two Ly-6A lacZ transgenic lines were analysed and compared with the Ly-6E lacZ BL1b transgenic line. As shown in the representative FACS histograms in Fig 2, no FDGpositive cells were found in the tissues of a non-transgenic control mouse, while both AZ1 and AZ2 mouse lines expressed the Ly-6A lacZ transgene in all four haematopoietic tissues. When the FACS-FDG pro®les of the Ly-6A lacZ tissues were then compared with those of the Ly-6E lacZ transgenic line BL1b, similar percentages of FDG-positive cells were observed in all four tissues.
To determine in which adult haematopoietic lineages the Ly-6A lacZ transgene expresses, we performed FDG-FACS analysis together with antibodies speci®c for T-lymphoid, B-lymphoid and myeloid cells. Table I shows the percentages of CD4-, CD8-, B220-and Mac-1-positive cells in the FDG + fraction of bone marrow, spleen, thymus and lymph node cells. As expected, predominant transgene expression was found in the T-lymphoid lineage, with some expression in the B-lymphoid and myeloid lineages. In addition, the percentages of FDG + cells of the different lineages found in the bone marrow, spleen and thymus of Ly-6E lacZ and Ly-6A lacZ transgenic adults were similar. Slight differences were found in the bone marrow CD4 and Mac-1 subsets, probably the result of low sample numbers. Taken together, these results strongly suggest that the lineage distribution of lacZ marker expression is not different for the Ly-6E and Ly-6A allelic transgene cassettes.
The Ly-6A lacZ transgene marks functional haematopoietic stem cells in adult bone marrow As the Ly-6A (Sca-1) protein is used extensively for the enrichment of HSCs from the bone marrow of adult mice and the Ly-6A lacZ transgene is expressed in 5±6% of adult bone marrow cells, we determined, using limiting dilution transplantation analysis, whether HSC activity was enriched in the FDG + population. To begin these studies, we ®rst examined what percentage of bone marrow cells were positive for transgene and endogenous Sca-1 expression. The FACS plots in Fig 3A show To test for the presence of HSCs in each of the phenotypically described populations, AZ1 and AZ2 bone marrow cells were sorted based on FDG and Sca-1 staining and injected in varying doses into irradiated adult recipients. At 4 months post transplantation, the recipient mice were tested for donor cell haematopoietic engraftment. As shown in Fig 3B, 
FDG
± sorted bone marrow. When these transplantation data were compared with equivalent sorting and transplantation data from Ly-6E lacZ transgenic mice (Miles et al, 1997; and data not shown) , no clear quantitative difference was found between Ly-6A lacZ and Ly-6E lacZ transgenics in bone marrow HSC activity enriched by FDG sorting.
Embryonic expression of the Ly-6A lacZ transgene in the AGM region is similar to that of the Ly-6E lacZ transgene The expression of the Ly-6A lacZ transgene in the haematopoietic lineages and the HSCs of the adult mouse led us to examine the speci®c expression pattern of this transgene during development. Localization of b-galactosidase expression by X-gal staining could indicate the ®rst site(s) of HSC appearance within the embryo. At E11, the expression pattern of Ly-6A lacZ was limited to the embryo body, with no expression in the yolk sac. The most striking X-gal staining was in the caudal tail region and the limb buds of AZ1 and AZ2 embryos (Fig 4A) . The caudal expression pattern along the dorso-ventral axis in the AZ1 and AZ2 lines was slightly more widespread than in BL1b embryos. However, the antero-posterior limit of expression in all three lines was con®ned to the posterior area containing the hindgut. The high-level limb bud expression was speci®c to the AZ1 and AZ2 lines and was not observed in the BL1b line. Furthermore, limb bud expression was not observed in other Ly-6E lacZ transgenic lines (Miles et al, 1997) . Thus, in mid-gestational mouse embryos the Ly-6A lacZ transgene was differentially expressed compared with the Ly-6E lacZ transgene.
Histological sectioning and staining was performed to determine in which embryonic tissues the Ly-6A lacZ transgene was expressed. In transverse sections from the truncal region of E11 AZ1, AZ2 and BL1b transgenic embryos, intense blue staining was observed in the epithelial cells lining the tubules of the pronephros and mesonephros (Fig 4B) . The staining pattern was identical between all three lines. As the dorsal aorta and the surrounding mesenchyme have been found to be the only area with the AGM region containing functional HSCs (de Bruijn et al, 2000) , we carefully examined the transverse sections for b-galactosidase activity at the site. No X-gal staining was found in the dorsal aorta or surrounding mesenchyme in any of the E11 sections examined from AZ1, AZ2 or BL1b transgenic lines. As the counterstaining may obscure the weak b-galactosidase signal from this area, we also examined transverse sections stained only with X-gal. While the pro/mesonephros showed high level b-galactosidase expression, not even weak X-gal staining was observed in the dorsal aorta or surrounding mesenchyme (data not shown). More sensitive FACS analysis veri®ed this result, strongly suggesting that AGM HSCs are negative or beneath the limits of detection for Ly-6A lacZ transgene expression.
DISCUSSION
The results of the studies presented here demonstrate that the Ly-6A lacZ transgene is transcribed consistently in a lineage-speci®c manner. This 14 kb cassette produced high Cell suspensions were stained with the FDG substrate and speci®c antibodies against the indicated cell lineage markers. At least 2´10 4 cells were examined. For the Ly-6E lacZ results, BL1b and BL19 transgenic adult mice were examined (see Miles et al, 1997) . For the Ly-6A lacZ results, AZ1 and AZ2 transgenic adult mice were used. Numbers in brackets (SD) are the standard deviation (three experiments performed). ND not done. levels of lacZ transcripts in the kidney as previously observed in Ly-6E lacZ transgenic mice and recapitulated the endogenous Ly-6A/E gene transcription expression pattern in adults. Although we examined only two Ly-6A lacZ transgenic lines, the levels of transcription of the transgene appeared to be identical between the AZ1 line, carrying eight copies of the transgene, and the AZ2 line, which had 20 copies of the transgene. Furthermore, the transcriptional levels were similar to that of the BL1b Ly-6E lacZ transgenic line which carries eight transgene copies (in homozygous animals). Thus, in the context of the lacZ reporter gene, the Ly-6A cassette does not appear to direct copy number dependent expression.
Both lines of Ly-6A lacZ transgenic adult mice express b-galactosidase similarly in haematopoietic cells. As expected from the previous results of¯ow cytometric analysis with the Sca-1 antibody, the Ly-6A lacZ transgene is expressed in all haematopoietic organs. Similar percentages of FDG-positive cells were found in the bone marrow, thymus, spleen and lymph nodes of the Ly-6A lacZ transgenic mice and corresponded to the percentages found in Ly-6E lacZ transgenic tissues. The predominant lineage Limiting dilution repopulation frequency of sorted FDG and Sca-1 stained bone marrow from Ly-6A lacZ bone marrow. AZ1 and AZ2 bone marrow was sorted into double-negative, double-positive and single-positive populations and injected into irradiated adult recipients in limiting numbers. Engraftment by donor cells was tested at greater than 4 months post transplantation and mice found to be more than 10% repopulated in the peripheral blood (as determined by lacZ semiquantitative polymerase chain reaction) were considered positive. The percentage of positive recipients is plotted on the ordinate and the number of sorted cells transplanted is plotted on the abscissa. Coded vertical bars represent the various sorted cell populations injected into the recipient mice. S Sca-1, F FDG and BM whole unsorted bone marrow. expressing the transgene is the CD4 subset of T cells. Also, cells of the CD8 subset, B and myeloid lineages were positive for transgene expression. Again, these data on the Ly-6A lacZ transgenic mice correspond well with the percentages of haematopoietic subsets positive for Ly-6E lacZ transgene expression.
Surprisingly, we did not observe the allele-speci®c differences noted by previous Sca-1 FACS analysis of the different allelic mouse strains and the percentages of FDG + haematopoietic cells were always slightly less than Sca-1 + cell percentages.
Indeed, in the Ly-6A lacZ transgenic mice we found FDG expression in some but not all functional adult repopulating HSCs. Flow cytometric sorting of FDG and Sca-1 double-stained bone marrow showed that not all adult HSCs were in the FDG fraction. While almost all HSCs are in the Sca-1 fraction, equal numbers of HSCs are found in the FDG + and FDG ± fractions. We observed this same distribution in the Ly-6E lacZ transgenic mice. The incomplete overlap in FDG and Sca-1 staining in bone marrow may be owing to the following: (1) Ly-6A/E molecules are surface GPI-linked glycoproteins, while b-galactosidase is cytoplasmic. Thus, the kinetics of protein production as well as protein half-life could be vastly different. (2) Not all the appropriate transcriptional control elements are contained within the 14kb Ly-6A/E cassettes or, more likely, position effect variegation has occurred. (3) The cell permeability to FDG is inef®cient. Either the entry of FDG into the cells is suboptimal or there is a loss through leakage, or both. (4) The lacZ gene is bacterial in origin and may be constrained in its expression in mice. For example, b-galactosidase production may reach a physiological threshold with higher levels being toxic and, thus, levels appear to be limited in the Ly-6A lacZ transgenic mice. At this time it is unclear which of these possibilities is responsible for suboptimal transgene expression. However, we have made several lines of transgenic mice in which mammalian genes such as the tal-1 transcription factor (unpublished observations) and the Bcl-2 antiapoptotic gene (unpublished observations) have been inserted into these cassettes. Both genes have been found to be expressed in haematopoietic cells.
Unlike the adult, differences in Ly-6A lacZ and Ly-6E lacZ expression were observed in transgenic embryos. The consistent expression in the limb buds and dorsal-caudal tail of the Ly-6A lacZ but not Ly-6E lacZ embryos strongly suggests that the proper regulatory elements are present, at least for these tissues. However, no functional HSCs have been isolated from either Ly-6A lacZ or Ly-6E lacZ AGMs. Sectioning and staining of this region (together with preliminary data with a Ly-6A GFP transgene) suggests that b-galactosidase expression is not high enough to yield an enrichment of HSCs from the AGM region.
Despite incomplete expression of the Ly-6A lacZ transgene in Sca-1 + cells, this transgene cassette does lead to faithful expression in some HSCs. For manipulation of HSCs in vivo and in vitro and for localization of HSCs within the whole animal, the Ly-6A cassette appears at present to be the best transgene construct, outside of targeting a marker gene by homologous recombination in embryonic stem cells. The clear advantage in the use of Ly-6A sequences for regulated expression in HSCs is the relative size of this gene and, particularly important, the 3¢ distal 1 kb regulatory sequence, compared with other genes encoding proteins expressed in HSCs. The genes encoding HSC marker proteins c-kit and AML-1 (Gokkel et al, 1992; Levanon et al, 2001 ) span over 100 kb of sequence and contain many exons and introns, thus making identi®cation of regulatory elements dif®cult. Thus, the further dissection of the regulatory elements of the Ly-6A gene expression cassette should lead to the generation of retroviral vectors for ef®cient transduction of and expression in HSCs.
